PE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>proteus syndrome</title>
<style>
    body {
        font-family: Arial, sans-serif;
        margin: 40px;
        display: flex;
    }
    img {
        max-width: 30%;
        height: 100%;
        margin-right: 20px;
    }
    .content {
        max-width: 70%;
    }
</style>
</head>
<body>
<img src="../images/proteussyndrome.jpg" alt="proteus syndrome">
<div class="content">
<h1>Proteus Syndrome</h1>

<p>[a] Artist/ Group/Tribe<br>
This image appears to be a historical medical illustration produced by an anonymous clinical draftsman or engraver. Such works were typically created within hospital settings or medical schools, where artists collaborated with physicians to record atypical anatomies for teaching and publication. The emphasis on precise contour, tonal modeling, and the neutral backdrop indicates a didactic purpose: to isolate the body as evidence and minimize narrative embellishment.</p>

<p>[b] Historical and Socio-Cultural context (time-frame)<br>
Medical atlases and journals of the late nineteenth and early twentieth centuries widely disseminated images like this one. In that period, the consolidation of “hospital medicine,” pathological museums, and standardized case histories shaped a visual culture of the clinic. Photography was increasingly used, yet engraving and lithography persisted because they allowed selective emphasis of diagnostically significant forms. The image inherits the era’s “medical gaze,” which sought objective truth in the visible body while reflecting contemporaneous concerns about classification, heredity, and social order.</p>

<p>[c] Symbolism and/ or iconography<br>
The term “Proteus” evokes the shape-shifting sea deity of Greek mythology, a metaphor for bodily variability and mosaic overgrowth. Iconographically, the profile view and circular vignette function like a specimen label: the subject is framed, isolated, and rendered legible for study. The head-and-torso crop privileges asymmetry and texture—visual cues that signpost pathology—while the lack of contextual setting suspends the figure in a clinical timelessness.</p>

<p>[d] Stylistic Significance (elements of art/ principles of design)<br>
The image relies on cross-hatching and controlled chiaroscuro to model volume and skin surface. Linearity governs form; the contour is crisp where diagnostic clarity is needed and softened where mass recedes. Balance is intentionally unsettled: the composition leads the eye along an oblique from the craniofacial profile to the thorax, accentuating disproportion. The reduction of background detail heightens figure-ground contrast, a strategy aligned with the atlas tradition that privileges clarity, seriality, and comparability across plates.</p>

<p>[e] Social / Cultural Inequities<br>
Historically, individuals with visible difference were frequently photographed or drawn without robust consent and, at times, exploited in clinical theaters or public exhibitions. Class, disability status, and institutional power shaped who became a subject of record and who retained bodily autonomy. Today, inequities persist in rare-disease care: families may face long diagnostic odysseys, travel for subspecialty consultation, and insurance barriers to genetic testing, imaging, and novel therapeutics. Ethical display and narration of such images require attention to dignity, privacy, and community perspectives.</p>

<p>[f] Description of Disease & Etiology<br>
Proteus syndrome is a sporadic, progressive overgrowth disorder caused by a postzygotic activating mutation in AKT1 (most commonly c.49G>A; p.E17K), leading to somatic mosaicism. The mutation activates the PI3K–AKT–mTOR pathway, driving tissue-selective overgrowth that can include bone, connective tissue, adipose, and vascular elements. Because the mutation occurs after fertilization, the condition is not inherited; severity and distribution reflect the timing and lineage of the mutated cell clone.</p>

<p>[g] Pathology Signs/Signifiers of Illness<br>
Characteristic features include segmental and asymmetric overgrowth of limbs and skull; dysregulated adipose deposits; osseous overgrowth with exostoses; vascular malformations; and pathognomonic cerebriform connective tissue nevi, often on the plantar surface. Complications include scoliosis, nerve compression, organomegaly in some cases, and a high risk of deep vein thrombosis and pulmonary embolism owing to a prothrombotic milieu. Although the artwork emphasizes craniofacial and truncal asymmetry, any inference about the specific individual depicted should be cautious; such images traditionally highlight features associated with the syndrome rather than constituting a definitive diagnosis.</p>

<p>[h] Treatment<br>
Management is multidisciplinary: orthopedic strategies (guided growth, epiphysiodesis, selective debulking), plastic and reconstructive procedures for contour and function, dermatologic care of connective tissue nevi, interventional radiology for vascular malformations, physiotherapy, pain management, and thrombosis surveillance with risk-adapted anticoagulation. Because pathogenesis centers on AKT activation, targeted agents are under study. Early-phase trials of AKT inhibitors (e.g., miransertib) have shown biomarker modulation and anecdotal clinical benefit in some patients; mTOR inhibition (e.g., sirolimus) has been used off-label in related overgrowth conditions. Decisions are individualized, weighing growth kinetics, surgical morbidity, thrombotic risk, and quality of life, with genetic counseling and psychosocial support integral to care.</p>

<p>[i] Social Determinants of Illness<br>
Outcomes are shaped by timely access to tertiary centers, availability of genetic testing, continuity of anticoagulation monitoring, rehabilitation services, assistive devices, and mental health support. Educational and workplace accommodations mitigate disability-related barriers, while social stigma can exacerbate isolation and delay care. Insurance coverage, transportation, caregiver capacity, and language access determine whether families can engage in repeated imaging, surgeries, and clinical trials that rare conditions often require.</p>

<p>[j] References and Citations</p>
<ul>
<li>Lindhurst MJ et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. New England Journal of Medicine (2011). https://www.nejm.org/doi/full/10.1056/NEJMoa1104017</li>
<li>Biesecker LG, Sapp JC. Proteus Syndrome. GeneReviews, NCBI Bookshelf (updated). https://www.ncbi.nlm.nih.gov/books/NBK1262/</li>
<li>Keppler-Noreuil KM et al. Phase 1/2 study of miransertib (ARQ 092) in Proteus syndrome: pharmacodynamic and clinical findings. Am J Med Genet A (2019). https://pubmed.ncbi.nlm.nih.gov/30663017/</li>
<li>NORD. Proteus Syndrome. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/proteus-syndrome/</li>
<li>Orphanet. Proteus syndrome (ORPHA:302). https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=302</li>
<li>GARD. Proteus syndrome. Genetic and Rare Diseases Information Center (NIH). https://rarediseases.info.nih.gov/diseases/7446/proteus-syndrome</li>
<li>Biesecker LG. The challenges of Proteus syndrome: diagnosis and management. Eur J Hum Genet (2006). https://www.nature.com/articles/5201643</li>
<li>Keppler-Noreuil KM, Rios JJ, Parker VE et al. PIK3CA/AKT-related overgrowth spectrum: an overview. Annu Rev Genomics Hum Genet (2016). https://www.annualreviews.org/doi/10.1146/annurev-genom-090314-025451</li>
</ul>
</div>
</body>
</ht